Drug intelligence / Profile preview

neostigmine + atropine + sugammadex

Development stage
Phase 4
Lead developer
Organon
Modality
Small Molecules
Administration
Intravenous
01

Overview

This is a combination of three drugs—neostigmine, atropine, and sugammadex—used in anesthesia practice for the reversal of neuromuscular blockade. - **Neostigmine** is an acetylcholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction, thereby reversing non-depolarizing neuromuscular blockade. - **Atropine** is a muscarinic antagonist administered alongside neostigmine to counteract its cholinergic side effects (such as bradycardia and increased secretions). - **Sugammadex** is a selective relaxant binding agent that encapsulates steroidal neuromuscular blocking agents (notably rocuronium and vecuronium), rapidly reversing their effects by reducing free drug concentration. The combination may be used to optimize recovery from moderate or deep neuromuscular blockade while minimizing the required dose of sugammadex and reducing associated costs or hypersensitivity risks[1]. Clinical studies have compared this combination with either agent alone for efficacy in reversal time, cognitive function outcomes, and postoperative nausea/vomiting[1][2][5][6].

02

Targets

AcetylcholinesterasemAChR (Muscarinic acetylcholine receptors)Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on neostigmine + atropine + sugammadex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on neostigmine + atropine + sugammadex.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call